Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

Fig. 2

Percentage confluence 7-days after treatment with azacitidine, carboplatin or combination azacitidine and carboplatin in (A) all cell lines, (B) BRCA-wildtype cell lines, and (C) BRCA-mutant cell lines. Data displayed is mean ± SEM of triplicates of three independent experiments

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us